Moderna's COVID boom was real — and so is the drop. The lesson starts with how fast revenue can vanish.
↓ scroll to read
✦ The bottom line
At the COVID peak, Moderna booked roughly $19B in a single year. In 2025 it booked $1.94B. The COVID emergency ended, demand normalized, and the revenue fell off a cliff. Moderna's whole thesis now is future products from its mRNA platform — not the shrinking COVID business.
↓ the brief below
✦ Teach me
When a boom is the baseline
A company that surges on a one-time event faces a brutal comparison afterward: every future year is measured against a peak that may never repeat. Moderna's COVID vaccine generated enormous, temporary demand. As the world moved on, revenue reset to a much lower, more normal level.
So Moderna's revenue chart looks alarming — but the right question isn't 'why did it fall?' (the boom ended), it's 'what's the new base, and what grows from here?'
Wall Street calls this
Revenue / post-peak normalization
Boom revenue can flatter a company for years and then disappear. Judging Moderna means ignoring the peak and asking what the *platform* can build next — which is a bet on the pipeline, not the past.
Revenue · fiscal year 2025
$1.94
B
Down from a COVID peak many times this size. Today's revenue comes from Spikevax/mNEXSPIKE (COVID) and the newer mRESVIA (RSV) — a much smaller, seasonal base than the boom years.
Source · 10-K · Results of Operations · FY2025 · Filed Feb 20, 2026
One caution when you read Moderna's quarters: vaccine sales are highly seasonal, concentrated in the fall/winter respiratory season. A single quarter (especially a quiet spring one) tells you almost nothing — so we anchor on the full year, and on what's coming through the pipeline.
⚠
Reset, not growing
Revenue has normalized far below the COVID peak. This isn't a growth story today — it's a bet that the platform creates the next products. Judge the pipeline, not the past.